The most clinically advanced BH3-mimetic drug is the BCL-2-specific inhibitor venetoclax, which is approved by the FDA and many other international regulatory authorities for therapy of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [7–9]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.